key: cord-0689473-mt0vt5gz authors: Haribabu, Jebiti; Balakrishnan, Nithya; Swaminathan, Srividya; Jerome, Peter; Gayathri, Dasararaju; Echeverria, Cesar; Bhuvanesh, Nattamai; Karvembu, Ramasamy title: Synthesis, cytotoxicity and docking studies (with SARS-CoV-2) of water-soluble binuclear Ru-p-cymene complex holding indole thiosemicarbazone ligand date: 2021-10-28 journal: Inorg Chem Commun DOI: 10.1016/j.inoche.2021.109029 sha: 859e098900dcb185e0c7cd51bb105b8ce72ed4e8 doc_id: 689473 cord_uid: mt0vt5gz A water-soluble binuclear organometallic Ru-p-cymene complex [Ru(η(6)-p-cymene)(η(2)-L)](2) (1) was prepared from (E)-2-((1H-indol-3-yl)methylene)-N-phenylhydrazine-1-carbothioamide (HL) and [RuCl(2)(p-cymene)](2) in methanol at room temperature under inert atmosphere. The structure of binuclear complex was analyzed by UV-Visible, FT-IR, NMR and mass spectroscopic methods. The solid-state structure of the complex was ascertained by single crystal X-ray diffraction technique. The complex exhibited pseudo-octahedral (piano-stool) geometry around Ru(II) ion. The cytotoxic property of the ligand and complex along with cisplatin was investigated against A549-lung, MCF7-breast, HeLa-cervical, HepG-2-liver, T24-urinary bladder and EA.hy926-endothelial cancer cells, and Vero-kidney epithelial normal cells. The complex exhibited superior activity than cisplatin against A549, HeLa and T24 cancer cells with the IC(50) values of 7.70, 11.2, and 5.05 µM, respectively. The complexes were cytotoxic specifically to the cancer cells. Molecular docking studies showed good binding potential of the ligand and complex with the spike protein and main protease of SARS-CoV-2, indicating the promising role of these compounds as antiviral compounds. Cancer is one of the major health concerns in the present society, which affects nearly all the parts of the body. The most frequent cancer affecting the people worldwide is lung cancer which has claimed 1.76 million lives among 2.09 million cases in 2018. Similarly, in midst of women, breast cancer is the most common cancer affecting an average of 2.1 million women each year. It was recently estimated that 15% of the cancerrelated deaths among women was due to breast cancer [1] . Early diagnosis approaches emphasize on administering the effective and timely treatment to the affected population [2] . Most of the cancer patients have a combination of treatments, such as surgery with chemotherapy and/or radiation therapy [3] . The idea of synthesizing transition metal complexes having chemotherapeutic properties has propagated due to an unmet clinical need for effective anticancer drugs [4] . Cisplatin, a Pt-based drug gained a widespread appreciation for its cytotoxic property establishing the trend of using metal-based drugs in chemotherapy. Along with cisplatin, oxaliplatin, carboplatin, nedaplatin and lobaplatin are various other Pt(II) coordination compounds which are employed in the chemotherapy. However, acquired Pt resistance and the lack of cellular selectivity of these drugs have paved the way for the development of new alternatives based on other metals and their corresponding complexes [5] . Provided the chemical similarity to the Pt group of transition metals, ruthenium (II/III) complexes have gained considerable interest as they have comparable ligand exchange kinetics to that of Pt. The in vivo mechanism of action of Ru complexes as anticancer agents varies from the conventional DNA-binding mechanism as exhibited by cisplatin [6] . [7] [8] . The first anticancer Ruarene system viz., [Ru(η 6 -benzene)(metronidazole)Cl 2 ] was reported in 1992 by Tocher et al [9] . In 2001, Dyson et al. [10] assessed the anticancer properties of complexes of the prototype [(η 6 -p-cymene)Ru(P-pta)Cl 2 ] termed as RAPTA-C. Similarly in the same year, Sadler and co-workers had reported the mechanism of action of their synthesized complexes of the type [Ru(η 6 -arene)(en)(Cl)] + named as RM175 [11] . So, the anticancer potential of the half-sandwich Ru(II) arene complexes of general formula [Ru(η 6arene)(X)(YZ)], wherein X is a leaving ligand and YZ is a bidendate chelating ligand, is currently of great interest [12] [13] [14] [15] . Indoles are thought as a privileged moiety in biological systems due to the valuable potentials they possess in human health care. This class of compounds is constituted in both proteins in the form of tryptophan and in bioactive alkaloid compounds like strychnine and lysergic acid diethylamide (LSD), marine natural products and fungal metabolites. In addition, the backbone structures of many drugs like vincristine and vinblastine (anticancer), sumatriptan (antimigraine), indomethacin [non-steroidal anti-inflammatory drug (NSAID)] and pindolol (antihypertensive) are composed of indole fragment as incorporation of such a versatile pharmacophore enhances their therapeutic potential [16, 17] . Thiosemicarbazones (TSCs) are mainly bidentate chelating ligands possessing a wide range of pharmacological properties such as antifungal, antibacterial, antioxidant, antitumor, etc. TSCs form stable metal complexes mainly via azomethine nitrogen and thionic sulphur, which in turn have better biological activities than their parent ligands [18] [19] [20] . TSCs-anchored half-sandwich Ru(II)-arene complexes are thought as promising therapeutic agents [21] [22] [23] . Usually, in Ru(II)-arene complexes bearing TSCs, thiocarbonyl sulphur coordinates with the metal ion either in the thione or thiol form, forming a fivemembered chelate ring, resulting in mononuclear cationic or neutral complexes. Although there are many remarkable reports on Ru(II)-arene complexes with TSCs, very few reports deal with binuclear Ru(II)-arene complexes where TSC ligands form either five-or fourmembered chelate ring via bidentate (N 1 ,S/N 2 ,S) chelation to Ru(II) ion in the anionic form. Su et al. had synthesized the binuclear Ru-arene complexes in a two-step reaction [24] . Our group is actively involved in the study of DNA/BSA binding and anticancer activity of the Ru-arene complexes with thiosemicarbazone/thiourea ligands [25] [26] [27] [28] . The reported complexes show good activity against cancer cells, inducing cell death through apoptosis. We previously reported the synthesis and DFT modelling of water soluble mono-and binuclear Ru(II)-p-cymene complexes formed based on the N-terminal substitution of indole TSC ligands, and the complexes exhibited potential anticancer activity against various cancer cells through apoptosis cell death [21] . In the present study, the synthesis of water-soluble binuclear Ru(II)-p-cymene complex was achieved by using N-phenyl indole TSC ligand. Transition metal complexes have advantages over other small molecular drugs by 4 virtue of wide spectrum of oxidation number, coordination states, multi-target effect, etc. Metal complexes may produce favorable and multi-target effects on the pathogens and viruses due to their unique metal centers [29] . Very rapid spread of SARS-CoV-2 has substantially increased the research towards the development of potential COVID-19 antiviral drugs and vaccines. Solubility is an important factor for the drug to enter the systemic circulation for showing a pharmacological response. Drugs that lack aqueous solubility show poor bioavailability and decreased absorption, which directly affect the therapeutic potency of the drugs. Hence, the need for water solubility of drugs is at large. These factors motivated us to design and synthesize a water-soluble binuclear Ru(II)-pcymene complex in one-step reaction. This complex was characterized by analytical and various spectroscopic tools. The piano-stool structure of the complex was determined by single crystal X-ray diffraction study. The anticancer activity of the compounds was investigated against six cancer and one normal cell lines. Molecular docking studies of the compounds with the spike protein and main protease of SARS-CoV-2 were investigated. All the required chemicals, solvents and biomolecules were purchased from Sigma Aldrich/Merck. The melting points were determined on a Lab India instrument and are uncorrected. FT-IR spectra were obtained as KBr pellets using a Nicolet-iS5 spectrophotometer. UV-visible spectra were recorded using a Shimadzu-2600 spectrophotometer. 1 H NMR spectra were recorded in CDCl 3 by using TMS as an internal standard on a Bruker 400 MHz spectrometer. reported in our earlier publications [17, 18, 30] . This indole based TSC ligand (HL, 58.8 mg, 0.02 mmol, 2 equiv.) in methanol (3 mL) was added to the suspension of [RuCl 2 (η 6 -p- X-ray diffraction data for complex 1 was collected from a Bruker Quest X-ray (fixed-chi geometry) diffractometer. The X-ray radiation employed was produced from a Mo-Iμs X-ray tube (K  = 0.71073Å). APEX3 software [31] [32] [33] was used to control the goniometer as well as for gathering the integrated intensity information for each reflection. The obtained data were corrected from absorption effects using the absorption correction program SADABS. Rest of the calculations and confirmations were done using the program PLATON (ADDSYM) [34] . Finally the structures were plotted and the final data were refined using the software Olex2 [35] . The stability of complex was analyzed by monitoring the electronic spectra of it in The hydrolysis of complex in the physiological medium was monitored by UV-visible absorption spectra at a temperature of 27 °C over a period of 24 h. The in vitro cytotoxicity of ligand and its Ru(II) complex was evaluated using [3- Finally the absorbance was read in the multi-well ELISA reader at 570 nm. The assay was repeated in triplicate and the mean absorbance and standard deviation were calculated. The cytotoxicity was then expressed in terms of IC 50 value. The % growth inhibition was analyzed using the formula [17] , The structures of HL, complex 1, chloroquine, hydroxychloroquine and remdesivir were converted into the pdb format using Chimera [37] , which were then given as input to the AutoDock 4.2 [38] . After adding the Gasteiger charges, the polar hydrogens were merged and then the compounds were saved in pdbqt format which is a special file format used by the AutoDock, containing information about the partial charges (Q), atom type (T) and rotatable bonds of the compounds. The receptors' crystallographic structures were retrieved from the protein data bank (PDB) [39] [40] . SARS CoV-2 spike protein (PDB id: 6M0J) [41] and the main protease (PDB id: 6Y2F) [42] structures in their pdb formats were given as input to the AutoDock, and further receptor preparations were carried out in AutoDock tools. For the spike protein, the ACE2 receptor was removed from the complex for carrying out molecular docking. The heteroatoms and water molecules were removed from both the proteins, after which the polar hydrogens and Kollman charges were assigned. The prepared proteins were then saved in pdbqt format. Interaction maps or the affinity grid maps were generated for the active site of the receptors prior to the actual docking process using the Autogrid program. Lamarckian genetic algorithm (LGA) was used to find the best possible conformation of the compounds binding with the receptors. Here, the protein was kept rigid while the ligand was flexible in the active site to find its conformation with the minimum binding energy. AutoDock program was used for docking of the compounds with the receptors. The docked conformations were analyzed using AutoDock tools. The conformations were ranked according to their binding energy, and the one with the lowest binding energy was the stable conformation of compound. The compound interactions at the binding site were analyzed using Chimera. (E)-2-((1H-indol-3-yl) The UV-visible spectrum (Fig. S1 ) of complex has been recorded in DMSO. Complex 1 showed two bands at 269 and 337 nm, which corresponded to ππ* and nπ* (intraligand) transitions, respectively. The dd transition in complex was characterized by a new band observed at 427 nm [21] . In the IR spectrum of complex 1, the C=N band was observed at 1494 cm -1 while the same band in the spectrum of ligand was found at 1549 cm -1 , indicating the coordination of azomethine N of TSC ligand to Ru(II) ion (Fig. S2) . The sulphur atom of ligand coordinated as thiolate (CS) to Ru(II) center as demonstrated by a band at 1217 cm -1 in the spectrum of complex 1 wherein a decrease in frequency was seen compared to that of the ligand (1287 cm -1 ) [21] [22] [23] . In the 1 shielded and gave signals at 2.01 and 5.00-5.50 ppm (Fig. S3) , respectively [22] . Complex 1 crystallized in monoclinic crystal system with space group P2 1 /n (Fig. 1 ). The crystal data and refinement parameters are provided in Table S1 . The complex (Table S2) [12, 24, 43] . The chloride counter ion involved in hydrogen bonding with the indole N-H and terminal N-H with the distances of 2.278 and 2.354 Å, respectively. These types of hydrogen bonds are rare in Ru-arene complexes containing TSC ligands, and it may play a subtle role in medicinal and bioorganometallic chemistry. The therapeutic potential of a metallodrug basically depends on its stability in the aqueous media. As the biological studies are normally done in 1% DMSO-water mixture, it is essential to know the stability of complex in this media for a period of 24 h. The UVvisible spectral profile for complex 1 is shown in Fig. S4 . The absorbance spectra of the complex recorded immediately and after 24 h did not display any noticeable change both in the intensities and positions of the bands, which clearly indicated the stability of complex under physiological conditions [15, 25, 44] . The Table 1 ) [21] [22] [23] [24] 46] and other ruthenium compounds [47] [48] [49] [50] [51] . As Ru complexes and TSC derivatives are known to possess antiviral properties, Water-soluble binuclear Ru(II)-p-cymene complex was prepared from indole thiosemicarbazone ligand in one step reaction and characterized by CHNS analysis, and various spectroscopic tools. The exact structure of complex was determined by X-ray diffraction study; the complex adopted a piano-stool geometry with two molecules of TSC The authors declare no competing financial interest. C53; World Health Organization, Globocan Risk factors and preventions of breast cancer Cancer and radiation therapy: Current advances and future directions Synthesis of palladium(II) complexes via Michael addition: Antiproliferative effects through ROS-mediated mitochondrial apoptosis and docking with SARS-CoV-2 Understanding and improving platinum anticancer drugs -Phenanthriplatin Designing ruthenium anticancer drugs: What have we learnt from the key drug candidates? Anticancer drug candidates face-to-face: A case story in medicinal inorganic chemistry NKP-1339, the first ruthenium-based anticancer drug on the edge to clinical application Studies on DNA damage and induction of SOS repair by novel multifunctional bioreducible compounds. II. A metronidazole adduct of a ruthenium-arene compound. Anti-Cancer Drug Des Challenges and opportunities in the development of organometallic anticancer drugs Inhibition of cancer cell growth by ruthenium(II)-arene complexes Synthesis, characterization and anticancer activity of a series of ketone-N 4 -substituted thiosemicarbazones and their ruthenium(II)-arene complexes Ruthenium(II)-arene complexes containing benzhydrazone ligands: Synthesis, structure and antiproliferative activity Transferrin serves as a mediator to deliver organometallic ruthenium(II) anticancer complexes into cells Enhanced anticancer activity of half-sandwich Ru(II)-p-cymene complex bearing heterocyclic hydrazone ligand Biological importance of the indole nucleus in recent years: A comprehensive review Zinc(II) complexes of indole thiosemicarbazones: DNA/protein binding, molecular docking and in vitro cytotoxicity studies Synthesis, structures and mechanistic pathways of anticancer activity of palladium(II) complexes with indole-3-carbaldehyde thiosemicarbazones Synthesis, DNA/protein binding, molecular docking, DNA cleavage and in vitro anticancer activity of nickel(II) bis(thiosemicarbazone) complexes Thiosemicarbazone(s)-anchored water soluble mono-and bimetallic Cu(II) complexes: Enzyme-like activities, biomolecular interactions, anticancer property and real-time live cytotoxicity Organometallic ruthenium complexes with thiosemicarbazone ligands: Synthesis, structure and cytotoxicity of Water-soluble mono-and binuclear Ru(η 6 -pcymene) complexes containing indole thiosemicarbazones: Synthesis, DFT modeling, biomolcular interactions, and in vitro anticancer activity through apoptosis Structurally different domains embedded half-sandwich arene Ru(II) complex: DNA/HSA binding and cytotoxic studies New dinuclear ruthenium-arene complexes containing thiosemicarbazone ligands: Synthesis, structure and cytotoxic studies Synthesis and anticancer activity of Coordination behavior of N, N′, N″-trisubstituted guanidine ligands in their Ru-arene complexes: Synthetic, DNA/protein binding, and cytotoxic studies Highly active copper(I) complexes of aroylthiourea ligands against cancer cells -Synthetic and biological studies Half-sandwich RuCl 2 (η 6 -p-cymene) core complexes containing sulfur donor aroylthiourea ligands: DNA and protein binding, DNA cleavage and cytotoxic studies Ruthenium complexes as antimicrobial agents Ru(II)-p-cymene thiosemicarbazone complexes as inhibitors of amyloid β (Aβ) peptide aggregation and Aβ-induced cytotoxicity A short history of SHELX Crystal structure refinement with SHELXL SHELXT -Integrated space-group and crystal-structure determination Single-crystal structure validation with the program PLATON OLEX2: A complete structure solution, refinement and analysis program EPR, cyclic voltammetric and biological activities of copper(II) complexes of salicylaldehyde N(4)-substituted thiosemicarbazone and heterocyclic bases UCSF Chimera -A visualization system for exploratory research and analysis Using AutoDock for ligand-receptor docking The protein data bank RCSB protein data bank: Biological macromolecular structures enabling research and education in fundamental biology, biomedicine, biotechnology and energy Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved a-ketoamide inhibitors New organoruthenium complexes with bioactive thiosemicarbazones as co-ligands: Potential anti-trypanosomal agents Unprecedented formation of palladium(II)-pyrazole based thiourea from chromone thiosemicarbazone and Exploring the cytotoxicity, uptake, cellular response and proteomics of mono-and dinuclear DNA light-switch complexes Screening organometallic binuclear thiosemicarbazone ruthenium complexes as potential antitumour agents: Cytotoxic activity and human serum albumin binding mechanism Recent advances in MOF-based nanoplatforms generating reactive species for chemodynamic therapy Recent advances in cell membrane coated metal-organic frameworks (MOFs) for tumor therapy Ultrasonic-assisted synthesis and DNA interaction studies of two new Ru complexes A multifunctional aminated UiO-67 metal-organic framework for enhancing antitumor cytotoxicity through bimodal drug delivery Impact of aliphatic acyl and aromatic thioamide substituents on the anticancer activity of Ru(II)-p-cymene complexes carrying acylthiourea ligands -In vitro and in vivo studies Computational evaluation of major components from plant essential oils as potent inhibitors Ru(1)−S(1)#1 equivalent atoms: #1 -x+1, -y+1 Synthesis, cytotoxicity and docking studies (with SARS-CoV-2) Ramasamy Karvembu * Piano-stool water-soluble binuclear organometallic Ru-p-cymene complex was synthesized and characterized. The complex exhibited superior activity than cisplatin